Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience

OBJECTIVES. Trastuzumab (H) and pertuzumab (P) with standard chemotherapy is approved for use in the neoadjuvant setting for human epidermal growth receptor 2 ‐positive patients. A retrospective analysis was performed of patients treated with dose‐dense (dd) doxorubicin and cyclophosphamide (AC) fol...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Oncologist
المؤلفون الرئيسيون: Singh, Jasmeet C., Mamtani, Anita, Barrio, Andrea, Morrow, Monica, Sugarman, Steven, Jones, Lee W., Yu, Anthony F., Argolo, Daniel, Smyth, Lilian M., Modi, Shanu, Schweber, Sarah, Boafo, Camilla, Patil, Sujata, Norton, Larry, Baselga, Jose, Hudis, Clifford A., Dang, Chau
التنسيق: Artigo
اللغة:Inglês
منشور في: AlphaMed Press 2017
الموضوعات:
Breast Cancer
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330708/
https://ncbi.nlm.nih.gov/pubmed/28167568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0268
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة